Covid-19 vaccine delivers adrenaline boost for stockmarkets
The news that 50 million doses of Pfizer's Covid-19 vaccine could be ready by the end of the year and 1.3 billion by 2021 has sparked euphoria on world markets.
![Nurse checking the temperature of a woman](https://cdn.mos.cms.futurecdn.net/KzmxqtMuvKWu7q9w984N73-415-80.jpg)
Pfizer’s vaccine trial has delivered a “shot of adrenaline for the markets”, says Russ Mould of AJ Bell. Fifty million doses could be ready by the end of the year and 1.3 billion by 2021, raising hopes that an end to the pandemic is finally in sight. The news caused euphoria on world markets, with the MSCI All-Country World Index closing at an all-time high and America’s S&P 500 setting a new record on Monday.
The FTSE 100 broke through the 6,000 level, rising more than 6% over the first two trading days of the week to register its highest closing level since June. The pan-European Stoxx 600 hit an eight-month high. Oil prices leapt by 9% and Japan’s Nikkei hit a 29-year peak (see page 7).
The wheel of fortune turns
Yet not all stocks were shining. America’s tech-heavy Nasdaq Composite Index fell by 1.5% on Monday, with Zoom, which has benefited from the work-from-home boom, plunging by almost 20%. By contrast, stocks hit hard by Covid-19 enjoyed a return to favour. In London, food-travel specialist SSP Group gained 52%, with aircraft engine maker Rolls-Royce up 43%.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
![https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg](https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748-320-80.jpg)
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The sudden shift away from tech stocks was the “biggest single-day market rotation I’ve witnessed” in 30 years covering markets, says John Authers on Bloomberg. The FAANG (Facebook, Amazon, Apple, Netflix and Google’s parent company, Alphabet) stocks have soared this year, but on Monday they underperformed the average S&P 500 stock by almost 8%. This sudden reversal could be the start of the long-predicted reflation trade, which would see investors shift away from expensive tech and into cheaper, more cyclical stocks.
Rising Covid-19 case numbers on both sides of the Atlantic could yet bring another bout of stockmarket turbulence, says Louis-Vincent Gave of Gavekal Research. But the market is “eager to turn the page” on the pandemic. Talk of a return to normal early next year means we could be heading for “an unprecedented economic rebound”. For long-suffering value investors things are finally looking up (see page 20).
The future is bright
The Pfizer news may prove “the beginning of the end” of the pandemic, but we still have a long way to go, says Cormac Mullen on Bloomberg. The “consensus view” is the same now as before the Pfizer update: a vaccine will come, but it will be “deep into 2021” before it is widely available.
Investors are right to be cheerful, says Robin Winkler of Deutsche Bank. The vaccine’s reported 90% efficacy is “at least as good as the best-case scenario” and government pre-orders mean that Pfizer is well-positioned to meet global demand. Finally, with vaccines from the likes of AstraZeneca and Moderna still in trials we don’t have all our eggs in one basket.
For now, investors are content to bask in the “warm glow” of good news, says Simon Jack for BBC News. Stockmarkets are about the future, and the vaccine results mean tomorrow looks better than today. “While the virus is not yet beaten it is beatable.”
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Skipton launches a retirement bond with monthly income – is it any good?
The building society has launched a new three-year fixed-rate bond for those aged 66 and over. Can it boost your retirement income?
By Katie Williams Published
-
Pensions: 140,000 pensioners to be hit by surprise tax demand
Tens of thousands of pensioners will be written to over the summer because their pensions have gone above the frozen income tax thresholds
By Chris Newlands Published
-
Netflix steams ahead of its competitors
Netflix has beaten its rivals, so how can it keep growing?
By Dr Matthew Partridge Published
-
What does a weak yen mean for Japanese stocks?
The Japanese yen has hit its lowest level against the US Dollar since 1986. What does it mean for its stock market?
By Alex Rankine Published
-
UK mid-caps: an improving outlook
UK mid-caps have perked up and the rally may run further, but long-term investors should remain selective
By Cris Sholto Heaton Published
-
The tobacco industry is going smoke-free - how to profit from it
Tobacco companies have realised their traditional products are on the wane. But new opportunities have opened up – and should prove lucrative
By Rupert Hargreaves Published
-
Is it time to invest in creative industries?
Any industrial strategy should not overlook the creative industries, one of our top national assets
By David C. Stevenson Published
-
Is Mercia Asset Management set for success?
Mercia Asset Management helps the government fund smaller companies in Britain’s regions. Should you invest?
By Rupert Hargreaves Published
-
British stocks set for a boost
British stocks are due for a bounce as the UK looks more stable compared to many economies
By Alex Rankine Published
-
Ocado shares jump by a fifth
Ocado takes a turn for the better after attractive profit forecasts were announced
By Dr Matthew Partridge Published